{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/menorrhagia/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"49315340-c2d5-5025-a18d-ab2347baae5b","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 68f74747-9527-4eef-b89c-b76bb77cd059 --><h2>Changes</h2><!-- end field 68f74747-9527-4eef-b89c-b76bb77cd059 -->","summary":null,"htmlStringContent":"<!-- begin item 673d3492-bce4-44d8-bc66-6e1d17ddf2a1 --><!-- begin field 4103d623-7f58-4ff0-a40d-673e6b5086bc --><p><strong>December 2018 </strong>— minor update. The sections on Diagnosis (particularly the section on Investigations) and Management have been updated to reflect new recommendations in the 2018 National Institute for Health and Care Excellence (NICE) guideline <em>Heavy menstrual bleeding: assessment and management [NICE, 2018]</em>. The management section has been restructured to simplify use.</p><p><strong>December 2017 </strong>— minor update. Added information about fetal malformations and effectiveness of hormonal contraceptives as an effect of topiramate.</p><p><strong>June to July 2017</strong> — reviewed. A literature search was conducted in June 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. </p><!-- end field 4103d623-7f58-4ff0-a40d-673e6b5086bc --><!-- end item 673d3492-bce4-44d8-bc66-6e1d17ddf2a1 -->","topic":{"id":"d4abfe41-b89f-5d51-8168-7ff98b4290f9","topicId":"4013d716-0ba5-4984-bfb1-8c7eca832ba8","topicName":"Menorrhagia","slug":"menorrhagia","lastRevised":"Last revised in December 2018","chapters":[{"id":"0e4b035a-9880-5848-b317-d92515f750d7","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"98c45e96-1179-53a4-9b74-a5f71fffaebd","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"73a36e11-2419-5f1f-9d0a-989641466fbf","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"49315340-c2d5-5025-a18d-ab2347baae5b","slug":"changes","fullItemName":"Changes"},{"id":"a232dfd0-a500-5e6b-9ead-3c3c94f0d2cf","slug":"update","fullItemName":"Update"}]},{"id":"cdc50c06-ff06-509a-be3e-1047ea50bc07","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"e5043cba-12e2-5f47-aac7-4e74d516a7fa","slug":"goals","fullItemName":"Goals"},{"id":"b1ea37fe-6d24-5529-9f7e-c0e49ccba796","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"cf03761e-6677-5ba5-ac47-f290b7cb66ec","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"24f740a2-df74-5305-b364-52d1fa68040a","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"913b3856-8846-53a2-86c7-f489c766e0f4","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"45c06974-d676-5c1e-bc8f-269a8c65df4f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"7d698fba-d82e-55be-bcc0-0ee11398e628","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"aa066829-e43c-5a83-b602-2680d838463a","slug":"definition","fullItemName":"Definition"},{"id":"37436c25-6db1-5e7c-b8fd-7590cd5ca25d","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e5c102c5-46d5-5096-bb8b-d2ef0960e353","slug":"causes","fullItemName":"Causes"},{"id":"b7f926cd-7de3-5b25-9697-78920cccf7b7","slug":"complications","fullItemName":"Complications"}]},{"id":"305d1c2b-5b47-5eda-adc5-03782afe2229","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"fc278e0b-a1a4-54d5-b44c-ddde104596ea","slug":"assessment","fullItemName":"Assessment"},{"id":"1d41d3f0-3049-510f-982a-9d9c39c5d52f","slug":"investigations-for-the-cause-of-menorrhagia","fullItemName":"Investigations for the cause of menorrhagia"}]},{"id":"5c051ed4-4e95-59b7-8bf1-c9e426198f5f","fullItemName":"Management","slug":"management","subChapters":[{"id":"e30d2783-35fc-5470-9fb3-b8a643f83450","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"324cd8d0-2857-5c2b-bd8e-ac2d83c5b55d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"c6b368dc-8409-55ee-8072-ffa3dc54a6f0","slug":"tranexamic-acid","fullItemName":"Tranexamic acid"},{"id":"13dd98d9-6054-5177-8564-df8c7ede9e5c","slug":"nonsteroidal-anti-inflammatory-drugs","fullItemName":"Nonsteroidal anti-inflammatory drugs"},{"id":"0e5ebc73-f73e-5d12-9e9a-82f8373fc507","slug":"oral-norethisterone","fullItemName":"Oral norethisterone"}]},{"id":"5964d183-6ca2-5e15-9a46-bd0c666e6146","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"443b20d0-895a-5b92-810b-17af26ab31e6","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"93531fdf-665e-5277-9d61-5b62984a866f","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"949f5d38-0e7a-59b8-a641-b1096ac7f3b3","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"dd5aaa9a-b897-51a6-b133-d7e4170711df","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"81610614-c77a-5340-b5b3-721aafb19cc3","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"83d1c27f-0003-5757-b8a1-90f777106d61","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"8fe218e8-4e7d-55af-9b5b-4f2bad344402","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"73a36e11-2419-5f1f-9d0a-989641466fbf","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"e2fd1a3e-592c-578f-9afc-7bbb08118f23","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 24ac5400-3320-4e95-a62c-c73c77702cb3 --><h3>Previous changes</h3><!-- end field 24ac5400-3320-4e95-a62c-c73c77702cb3 -->","summary":null,"htmlStringContent":"<!-- begin item 277055a7-f2b0-498b-91a1-8b51b9bc0f0c --><!-- begin field c2fae412-5bd8-4356-9e2e-2741491e47e1 --><p><strong>August </strong><strong>2015 </strong>— minor update. The section on Prescribing information has been updated to reflect expert opinion and the NHS Regional Drugs and Therapeutics Centre Bulletin in relation to the recommendation for mefenamic acid.</p><p><strong>February 2013 </strong>— minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>October 2012 </strong>— minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>September 2012 </strong>— minor update. Black triangle removed from Qlaira<sup>® </sup>tablets.</p><p><strong>August 2012 </strong>— reviewed. A literature search was conducted in July 2012 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of the topic. No changes to clinical recommendations have been made.</p><p><strong>May 2011 </strong>— information on Qlaira<sup>®</sup>, a quadraphasic combined oral contraceptive pill, was added to prescribing information. Issued in June 2011.</p><p><strong>May 2011 </strong>— the 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>January 2011 </strong>— correction to the dosage and usage instructions for tranexamic acid. Prescription also corrected. Issued in January 2011.</p><p><strong>October 2010 </strong>— topic structure revised to ensure consistency across CKS topics — no changes to clinical recommendations have been made.</p><p><strong>September 2010 </strong>— minor update. A prescription for Rigevidon<sup>®</sup>, another new ethinylestradiol plus levonorgestrel combined oral contraceptive pill, has been added. Issued in September 2010.</p><p><strong>June 2010 </strong>— minor update. A prescription for Levest<sup>®</sup>, a new ethinylestradiol plus levonorgestrel combined oral contraceptive pill, has been added. Issued in June 2010.</p><p><strong>February 2009 </strong>— minor update to the combined oral contraceptive pill prescriptions. The upper age limit for use has been reduced to 50 years. Issued in March 2009.</p><p><strong>June to September 2007 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. The most important change to the recommendations is that the levonorgestrel-releasing intrauterine system is now recommended first-line for most women with heavy menstrual bleeding.</p><p><strong>October 2005 </strong>— minor technical update. Issued in November 2005.</p><p><strong>July 2005 </strong>— updated to incorporate the <em>Referral guidelines for suspected cancer </em>published by the National Institute for Health and Care Excellence. Issued in July 2005.</p><p><strong>February 2005 </strong>— updated to include prescribing advice from the Committee on Safety of Medicines on the effect of depot medroxyprogesterone acetate contraception on bones. Issued in February 2005.</p><p><strong>May 2004 </strong>— reviewed. Validated in September 2004 and issued in November 2004.</p><p><strong>March 2002 </strong>— updated to incorporate referral advice from the National Institute for Health and Care Excellence. Issued in April 2002.</p><p><strong>June 2001 </strong>— reviewed. Validated in July 2001 and issued in October 2001.</p><p><strong>October 1998 </strong>— written.</p><!-- end field c2fae412-5bd8-4356-9e2e-2741491e47e1 --><!-- end item 277055a7-f2b0-498b-91a1-8b51b9bc0f0c -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}